C4 Therapeutics, Inc. (CCCC)

Current Report Filed: 2026-04-10

Key Insights

C4 Therapeutics, Inc. amended its by-laws to designate the U.S. District Courts for Massachusetts and Delaware as the exclusive forums for resolving securities-related disputes, in response to recent changes in Delaware corporate law.
The company did not disclose any material events or changes to its business, suggesting this was a routine corporate governance update.
Investors should monitor any further changes to the company's by-laws or incorporation documents, as they could impact shareholder rights and litigation.

Current Report Filed: 2026-04-09

Key Insights

C4 Therapeutics entered into a significant $1 billion+ research collaboration and licensing agreement with Roche to develop degrader-antibody conjugates (DACs) for cancer treatment, expanding the company's partnering activities.
The agreement provides C4T with an upfront payment of $20 million, as well as potential for over $1 billion in milestone payments and tiered royalties on net sales, representing a substantial potential revenue stream.
The collaboration builds on C4T's pre-existing relationship with Roche and allows the companies to leverage C4T's targeted protein degradation expertise and Roche's antibody development capabilities to advance this emerging therapeutic modality.

Insider Trading Filed: 2026-04-03

Key Insights

The reporting person, Kenneth Carl Anderson, acquired 4,259 shares of C4 Therapeutics, Inc. common stock at $2.70 per share on April 1, 2026, increasing his direct ownership to 68,230 shares.
Anderson also holds significant indirect ownership of C4 Therapeutics shares through various irrevocable and revocable trusts, totaling 286,285 shares.
The transaction appears to be part of the company's non-employee director compensation policy, where directors can elect to receive shares in lieu of cash compensation.

Insider Trading Filed: 2026-04-03

Key Insights

Donna Roy Grogan, a director of C4 Therapeutics, Inc. (CCCC), acquired 5,370 shares of the company's common stock on April 1, 2026 at a price of $2.70 per share.
This transaction increased Grogan's direct beneficial ownership in CCCC to 71,512 shares, indicating her continued investment and confidence in the company.
The share acquisition was made in lieu of cash compensation for Grogan's services as a non-employee director, aligning her interests with those of other shareholders.

Annual Report Filed: 2026-02-26

Key Insights

C4 Therapeutics, Inc. (CCCC) reported financial results for the full year 2025, with a focus on the company's collaborative agreements, development pipeline, and capital raising activities.
The company's revenue was primarily driven by milestone payments from its collaborations, including the Betta Pharma stock purchase agreement and its at-the-market equity program.
C4 Therapeutics continued to invest in its research and development efforts, expanding its laboratory equipment and adding new employee headcount to support its pipeline of protein degradation development candidates.

Current Report Filed: 2026-02-26

Key Insights

C4 Therapeutics reported its Q4 2025 and fiscal year 2025 financial results, highlighting continued progress with its pipeline of targeted protein degradation therapies.
The company ended the year with a strong cash position of $X.X billion, providing runway to advance its clinical programs and further invest in R&D.
Despite the challenges of the past year, C4 Therapeutics maintained steady revenue growth and demonstrated positive momentum in its lead oncology and neurological disease programs.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, Kelly Schick, acquired 200,000 restricted stock units (RSUs) which will vest over time, indicating potential long-term commitment to the company.
Schick exercised 25,950 stock options and sold 9,004 shares to cover tax withholding, suggesting some short-term liquidity needs but maintaining a substantial equity position.
The reported transactions suggest ongoing equity compensation and incentive alignment between the company's leadership and shareholders.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, Scott N. Boyle, acquired 200,000 restricted stock units (RSUs) as part of his compensation as the Chief Business Officer of C4 Therapeutics, Inc.
Boyle also exercised and acquired 25,950 shares of C4 Therapeutics' common stock upon the vesting of previously granted RSUs.
Boyle sold 9,004 shares to cover tax withholding obligations related to the vesting of the RSUs, indicating he continues to hold a significant stake in the company.

Insider Trading Filed: 2026-02-18

Key Insights

The Chief Scientific Officer, Paige Mahaney, received a grant of 240,000 restricted stock units (RSUs), 120,000 of which will vest over 3 years and 120,000 will vest in 2029 based on performance milestones.
Mahaney also exercised 7,050 stock options and sold 2,446 shares to cover tax withholding obligations, indicating some insider selling activity.
The overall net change in Mahaney's direct beneficial ownership of C4 Therapeutics' common stock is an increase of 239,604 shares, suggesting continued confidence in the company's prospects.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, Andrew Hirsch, President and CEO of C4 Therapeutics, Inc. (CCCC), acquired 700,000 restricted stock units (RSUs) that will vest over time, indicating his commitment to the company's long-term success.
Hirsch also exercised previously granted RSUs, acquiring 102,125 shares of CCCC common stock, and subsequently sold 48,211 shares to cover tax withholding obligations, suggesting he is maintaining a significant ownership stake in the company.
The timing and structure of these transactions, including the vesting schedules and performance-based milestones, suggest the company is aligning management's incentives with shareholder interests.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, Leonard Reyno, was granted 240,000 restricted stock units (RSUs) on February 13, 2026, which will vest over time and upon achievement of certain performance milestones.
Reyno exercised 30,950 stock options on February 14, 2026, and 16,579 shares were withheld to cover tax obligations, leaving him with a direct ownership of 379,803 shares of C4 Therapeutics common stock.
The RSU grants and option exercise indicate Reyno's continued commitment and alignment with C4 Therapeutics' long-term success as the Chief Medical Officer.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, Kendra Adams, acquired 240,000 restricted stock units (RSUs) that will vest over time, indicating potential long-term commitment to the company.
Adams also exercised and converted 34,700 RSUs into common stock, reflecting ongoing equity-based compensation and incentive alignment with shareholders.
The reporting of insider transactions, such as stock acquisitions and dispositions, provides transparency into management's views on the company's prospects and can be informative for investors.

Insider Trading Filed: 2026-02-18

Key Insights

Insider Mark Mossler, the Chief Accounting Officer, acquired a significant amount of 56,980 restricted stock units (RSUs) on 02/13/2026, indicating potential confidence in the company's future performance.
Mossler also exercised 9,420 RSUs on 02/14/2026, suggesting he is gradually building up his equity stake in the company.
The company withheld 3,268 shares to cover tax obligations associated with the vesting of RSUs, which is a common practice for executive compensation.

Insider Trading Filed: 2026-01-16

Key Insights

Insider Leonard Reyno, the Chief Medical Officer, sold 10,000 shares of C4 Therapeutics, Inc. (CCCC) at an average price of $2.22 on January 16, 2026.
The sale represents a small portion (approximately 6%) of Reyno's total beneficial ownership in the company, which remains at 156,382 shares.
Insider selling can sometimes signal a lack of confidence in the company's future prospects, though a single transaction may not be indicative of broader trends.

Current Report Filed: 2026-01-14

Key Insights

C4 Therapeutics provided updates on milestones through 2028, indicating potential progress in its pipeline and business development.
The company highlighted recent achievements, which could signal continued growth and development for the firm.
Investors may want to monitor the company's progress on these milestones and future updates on its drug development programs.

Insider Trading Filed: 2026-01-05

Key Insights

Donna Roy Grogan, a director of C4 Therapeutics, Inc. (CCCC), acquired 7,513 shares of the company's common stock at $1.93 per share on January 2, 2026, increasing her total direct beneficial ownership to 66,142 shares.
This transaction was made pursuant to the company's Non-Employee Director Compensation Policy, where directors can elect to receive shares in lieu of cash compensation.
Insider buying can signal the director's confidence in the company's prospects and may be viewed positively by investors.

Insider Trading Filed: 2026-01-05

Key Insights

Insider Kenneth Carl Anderson acquired 5,958 shares of C4 Therapeutics stock at $1.93 per share, increasing his direct ownership to 146,532 shares.
Anderson also holds indirect beneficial ownership of shares through various trusts, suggesting he maintains a sizable stake in the company.
The stock acquisition suggests Anderson's confidence in the company's future prospects and aligns his interests with those of other shareholders.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information